share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax製藥 | 8-K:重大事件
美股SEC公告 ·  07/15 08:04

Moomoo AI 已提取核心訊息

Virpax Pharmaceuticals, Inc., a Delaware-incorporated emerging growth company, has reported the issuance of 1,975,283 shares of common stock on July 11, 2024. This issuance was a result of investors exercising warrants previously issued by the company. The company received proceeds of approximately $2.67 million from this exercise. Following the issuance, the total number of outstanding shares of Virpax Pharmaceuticals' common stock increased to 4,813,181. The shares were issued under a registration statement on Form S-1, which was declared effective on May 14, 2024. The company's common stock is registered on The Nasdaq Capital Market under the trading symbol VRPX. The report was officially signed by Gerald Bruce, the Chief Executive Officer of Virpax Pharmaceuticals, on July 15, 2024.
Virpax Pharmaceuticals, Inc., a Delaware-incorporated emerging growth company, has reported the issuance of 1,975,283 shares of common stock on July 11, 2024. This issuance was a result of investors exercising warrants previously issued by the company. The company received proceeds of approximately $2.67 million from this exercise. Following the issuance, the total number of outstanding shares of Virpax Pharmaceuticals' common stock increased to 4,813,181. The shares were issued under a registration statement on Form S-1, which was declared effective on May 14, 2024. The company's common stock is registered on The Nasdaq Capital Market under the trading symbol VRPX. The report was officially signed by Gerald Bruce, the Chief Executive Officer of Virpax Pharmaceuticals, on July 15, 2024.
維帕克斯藥品公司是一家總部位於特拉華州的新興成長型企業,於2024年7月11日報告發行了1975283股普通股。此次發行是投資者行使公司之前發行的權證的結果。公司從本次行使中獲得了大約267萬美元的收益。發行後,維帕克斯藥品公司普通股的總流通股份增加到4813181股。這些股票是在S-1表格的註冊聲明下發行的,該表格於2024年5月14日生效。公司的普通股在納斯達克納斯達克資本市場上註冊,交易代碼爲VRPX。該報告由維帕克斯藥品公司首席執行官傑拉爾德·布魯斯於2024年7月15日正式簽署。
維帕克斯藥品公司是一家總部位於特拉華州的新興成長型企業,於2024年7月11日報告發行了1975283股普通股。此次發行是投資者行使公司之前發行的權證的結果。公司從本次行使中獲得了大約267萬美元的收益。發行後,維帕克斯藥品公司普通股的總流通股份增加到4813181股。這些股票是在S-1表格的註冊聲明下發行的,該表格於2024年5月14日生效。公司的普通股在納斯達克納斯達克資本市場上註冊,交易代碼爲VRPX。該報告由維帕克斯藥品公司首席執行官傑拉爾德·布魯斯於2024年7月15日正式簽署。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息